SEARCH

SEARCH BY CITATION

References

  • 1
    Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, Kvarstein G, Stubhaug A. Assessment of pain. Br J Anaesth 2008; 101: 1724.
  • 2
    Olesen AE, Andresen T, Staahl C, Drewes AM. Human experimental pain models for assessing the therapeutic efficacy of analgesic drugs. Pharmacol Rev 2012; 64: 722779.
  • 3
    Saab C. Visualizing the complex brain dynamics of chronic pain. J Neuroimmune Pharmacol 2012 [Epub ahead of print].
  • 4
    Prichep LS, John ER, Howard B, Merkin H, Hiesiger EM. Evaluation of the pain matrix using EEG source localization: a feasibility study. Pain Med 2011; 12: 12411248.
  • 5
    Chizh BA, Priestley T, Rowbotham M, Schaffler K. Predicting therapeutic efficacy – experimental pain in human subjects. Brain Res Rev 2009; 60: 243254.
  • 6
    Dumermuth G, Ferber G, Herrmann WM, Hinrichs H, Kunkel H, International pharmaco-EEG group (IPEG). Committee on standardization of data acquisition and analysis in pharmaco-EEG investigations. Neuropsychobiology 1987; 17: 213218.
  • 7
    Knott VJ. Quantitative EEG methods and measures in human psychopharmacological research. Hum Psychopharmacol 2000; 15: 479498.
  • 8
    Versavel M, Leonard JP, Herrmann WM. Standard operating procedure for the registration and computer-supported evaluation of pharmaco-EEG data. ‘EEG in Phase I’ of the Collegium Internationale Psychiatriae Scalarum (CIPS). Neuropsychobiology 1995; 32: 166170.
  • 9
    Jobert M, Wilson FJ, Ruigt GS, Brunovsky M, Prichep LS, Drinkenburg WH, IPEG Pharmaco-EEG Guidelines Committee. Guidelines for the recording and evaluation of pharmaco-EEG data in man: the International Pharmaco-EEG Society (IPEG). Neuropsychobiology 2012; 66: 201220.
  • 10
    Buzsaki G, Anastassiou CA, Koch C. The origin of extracellular fields and currents – EEG, ECoG, LFP and spikes. Nat Rev Neurosci 2012; 13: 407420.
  • 11
    Staahl C, Drewes AM. Experimental human pain models: a review of standardised methods for preclinical testing of analgesics. Basic Clin Pharmacol Toxicol 2004; 95: 97111.
  • 12
    Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet 2011; 377: 22262235.
  • 13
    Khodayari-Rostamabad A, Reilly JP, Hasey G, Debruin H. Using pre-treatment EEG data to predict response to SSRI treatment for MDD. Conf Proc IEEE Eng Med Biol Soc 2010; 2010: 61036106.
  • 14
    Nunez PL, Srinivasan R. Electric Fields of the Brain: The Neurophysics of EEG, 2ed edn. New York: Oxford University Press, 2006.
  • 15
    Hughes JR, John ER. Conventional and quantitative electroencephalography in psychiatry. J Neuropsychiatry Clin Neurosci 1999; 11: 190208.
  • 16
    Nuwer MR, Lehmann D, da Silva FL, Matsuoka S, Sutherling W, Vibert JF. IFCN guidelines for topographic and frequency analysis of EEGs and EPs. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl 1999; 52: 1520.
  • 17
    John ER, Prichep LS. The anesthetic cascade: a theory of how anesthesia suppresses consciousness. Anesthesiology 2005; 102: 447471.
  • 18
    Constant I, Sabourdin N. The EEG signal: a window on the cortical brain activity. Paediatr Anaesth 2012; 22: 539552.
  • 19
    Olejniczak P. Neurophysiologic basis of EEG. J Clin Neurophysiol 2006; 23: 186189.
  • 20
    Durka PJ. From wavelets to adaptive approximations: time-frequency parametrization of EEG. Biomed Eng Online 2003; 2: 1.
  • 21
    Samar VJ, Bopardikar A, Rao R, Swartz K. Wavelet analysis of neuroelectric waveforms: a conceptual tutorial. Brain Lang 1999; 66: 760.
  • 22
    Tonner PH, Bein B. Classic electroencephalographic parameters: median frequency, spectral edge frequency etc. Best Pract Res Clin Anaesthesiol 2006; 20: 147159.
  • 23
    Fabiani M, Gratton G, Coles MGH. Event-related brain potentials – methods, theory, and applications. In: Handbook of Psychophysiology, 2ed edn. eds Cacioppo JT , Tassinary LG , Bertson GG . Cambridge: Cambridge University Press, 2000; 5583.
  • 24
    Bromm B, Lorenz J. Neurophysiological evaluation of pain. Electroencephalogr Clin Neurophysiol 1998; 107: 227253.
  • 25
    Greenwald MK, Roehrs TA. Mu-opioid self-administration vs passive administration in heroin abusers produces differential EEG activation. Neuropsychopharmacology 2005; 30: 212221.
  • 26
    Handwerker HO, Kobal G. Psychophysiology of experimentally induced pain. Physiol Rev 1993; 73: 639671.
  • 27
    Zaslansky R, Sprecher E, Katz Y, Rozenberg B, Hemli JA, Yarnitsky D. Pain-evoked potentials: what do they really measure? . Electroencephalogr Clin Neurophysiol 1996; 100: 384391.
  • 28
    Mouraux A, Plaghki L. Are laser-evoked brain potentials modulated by attending to first or second pain? Pain 2007; 129: 321331.
  • 29
    Mouraux A, Iannetti GD. Across-trial averaging of event-related EEG responses and beyond. Magn Reson Imaging 2008; 26: 10411054.
  • 30
    Larijani GE, Goldberg ME. Alfentanil hydrochloride: a new short-acting narcotic analgesic for surgical procedures. Clin Pharm 1987; 6: 275282.
  • 31
    Egan TD, Minto CF, Hermann DJ, Barr J, Muir KT, Shafer SL. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology 1996; 84: 821833.
  • 32
    Freye E, Buhl R, Ciaramelli F. Opioids with different affinity for subreceptors induce different effects on early and late sensory evoked potentials (SEP) in man. NIDA Res Monogr 1986; 75: 551554.
  • 33
    Arendt-Nielsen L, Oberg B, Bjerring P. Analgesic efficacy of i.m. alfentanil. Br J Anaesth 1990; 65: 164168.
  • 34
    Chapman CR, Hill HF, Saeger L, Gavrin J. Profiles of opioid analgesia in humans after intravenous bolus administration: alfentanil, fentanyl and morphine compared on experimental pain. Pain 1990; 43: 4755.
  • 35
    Petersen-Felix S, Arendt-Nielsen L, Bak P, Fischer M, Zbinden AM. Psychophysical and electrophysiological responses to experimental pain may be influenced by sedation: comparison of the effects of a hypnotic (propofol) and an analgesic (alfentanil). Br J Anaesth 1996; 77: 165171.
  • 36
    Kalkman CJ, Leyssius AT, Bovill JG. Influence of high-dose opioid anesthesia on posterior tibial nerve somatosensory cortical evoked potentials: effects of fentanyl, sufentanil, and alfentanil. J Cardiothorac Anesth 1988; 2: 758764.
  • 37
    Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician 2008; 11: S133153.
  • 38
    Arendt-Nielsen L, Nielsen JC, Bjerring P. Double-blind, placebo controlled comparison of paracetamol and paracetamol plus codeine – a quantitative evaluation by laser induced pain. Eur J Clin Pharmacol 1991; 40: 241247.
  • 39
    Hummel T, Huber H, Menzel S, Kobal G. Tonic versus phasic pain: dose-related effects of ketoprofen. Eur J Clin Pharmacol 1995; 49: 714.
  • 40
    Schubert A, Drummond JC, Peterson DO, Saidman LJ. The effect of high-dose fentanyl on human median nerve somatosensory-evoked responses. Can J Anaesth 1987; 34: 3540.
  • 41
    Hume AL, Durkin MA. Central and spinal somatosensory conduction times during hypothermic cardiopulmonary bypass and some observations on the effects of fentanyl and isoflurane anesthesia. Electroencephalogr Clin Neurophysiol 1986; 65: 4658.
  • 42
    McPherson RW, Sell B, Traystman RJ. Effects of thiopental, fentanyl, and etomidate on upper extremity somatosensory evoked potentials in humans. Anesthesiology 1986; 65: 584589.
  • 43
    Sawynok J. The therapeutic use of heroin: a review of the pharmacological literature. Can J Physiol Pharmacol 1986; 64: 16.
  • 44
    Stoermer R, Drewe J, Dursteler-Mac Farland KM, Hock C, Mueller-Spahn F, Ladewig D, Stohler R, Mager R. Safety of injectable opioid maintenance treatment for heroin dependence. Biol Psychiatry 2003; 54: 854861.
  • 45
    Coda B, Tanaka A, Jacobson RC, Donaldson G, Chapman CR. Hydromorphone analgesia after intravenous bolus administration. Pain 1997; 71: 4148.
  • 46
    Bromm B, Meier W, Scharein E. Imipramine reduces experimental pain. Pain 1986; 25: 245257.
  • 47
    Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 1989; 251: 477483.
  • 48
    Saletu B, Saletu M, Brown M, Stern J, Sletten I, Ulett G. Hypno-analgesia and acupuncture analgesia: a neurophysiological reality? Neuropsychobiology 1975; 1: 218242.
  • 49
    Lotsch J, Kobal G, Geisslinger G. No contribution of morphine-6-glucuronide to clinical morphine effects after short-term administration. Clin Neuropharmacol 1998; 21: 351354.
  • 50
    Lotsch J, Kobal G, Stockmann A, Brune K, Geisslinger G. Lack of analgesic activity of morphine-6-glucuronide after short-term intravenous administration in healthy volunteers. Anesthesiology 1997; 87: 13481358.
  • 51
    Quante M, Scharein E, Zimmermann R, Langer-Brauburger B, Bromm B. Dissociation of morphine analgesia and sedation evaluated by EEG measures in healthy volunteers. Arzneimittelforschung 2004; 54: 143151.
  • 52
    Staahl C, Krarup AL, Olesen AE, Brock C, Graversen C, Drewes AM. Is electrical brain activity a reliable biomarker for opioid analgesia in the gut? Basic Clin Pharmacol Toxicol 2011; 109: 321327.
  • 53
    Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 1991; 41: 326344.
  • 54
    Bromm B, Ganzel R, Herrmann WM, Meier W, Scharein E. Pentazocine and flupirtine effects on spontaneous and evoked EEG activity. Neuropsychobiology 1986; 16: 152156.
  • 55
    Bromm B, Ganzel R, Herrmann WM, Meier W, Scharein E. The analgesic efficacy of flupirtine in comparison to pentazocine and placebo assessed by EEG and subjective pain ratings. Postgrad Med J 1987; 63 (Suppl. 3): 109112.
  • 56
    Servin FS, Billard V. Remifentanil and other opioids. Handb Exp Pharmacol 2008; 182: 283311.
  • 57
    Noh GJ, Kim KM, Jeong YB, Jeong SW, Yoon HS, Jeong SM, Kang SH, Linares O, Kern SE. Electroencephalographic approximate entropy changes in healthy volunteers during remifentanil infusion. Anesthesiology 2006; 104: 921932.
  • 58
    Schmidt GN, Scharein E, Siegel M, Muller J, Debener S, Nitzschke R, Engel A, Bischoff P. Identification of sensory blockade by somatosensory and pain-induced evoked potentials. Anesthesiology 2007; 106: 707714.
  • 59
    Monk JP, Beresford R, Sufentanil WA. A review of its pharmacological properties and therapeutic use. Drugs 1988; 36: 286313.
  • 60
    Kimovec MA, Koht A, Sloan TB. Effects of sufentanil on median nerve somatosensory evoked potentials. Br J Anaesth 1990; 65: 169172.
  • 61
    Reeves RR, Burke RS. Tramadol: basic pharmacology and emerging concepts. Drugs Today (Barc) 2008; 44: 827836.
  • 62
    Thurauf N, Fleischer WK, Liefhold J, Schmid O, Kobal G. Dose dependent time course of the analgesic effect of a sustained-release preparation of tramadol on experimental phasic and tonic pain. Br J Clin Pharmacol 1996; 41: 115123.
  • 63
    Truini A, Panuccio G, Galeotti F, Maluccio MR, Sartucci F, Avoli M, Cruccu G. Laser-evoked potentials as a tool for assessing the efficacy of antinociceptive drugs. Eur J Pain 2010; 14: 222225.
  • 64
    Lekic D, Cenic D. Pain and tooth pulp evoked potentials. Clin Electroencephalogr 1992; 23: 3746.
  • 65
    Hummel T, Kraetsch HG, Lotsch J, Hepper M, Liefhold J, Kobal G. Analgesic effects of dihydrocodeine and tramadol when administered either in the morning or evening. Chronobiol Int 1995; 12: 6272.
  • 66
    Hummel T, Hummel C, Friedel I, Pauli E, Kobal G. A comparison of the antinociceptive effects of imipramine, tramadol and anpirtoline. Br J Clin Pharmacol 1994; 37: 325333.
  • 67
    Hummel T, Roscher S, Pauli E, Frank M, Liefhold J, Fleischer W, Kobal G. Assessment of analgesia in man: tramadol controlled release formula vs. tramadol standard formulation. Eur J Clin Pharmacol 1996; 51: 3138.
  • 68
    Chambon JP, Brochard J, Hallot A, Heaulme M, Brodin R, Roncucci R, Biziere K. CM 40907: a structurally novel anticonvulsant in mice, rats and baboons. J Pharmacol Exp Ther 1985; 233: 836844.
  • 69
    Schaffler K, Wauschkuhn CH, Gierend M. Analgesic potency of a new anticonvulsant drug versus acetylsalicylic acid via laser somatosensory evoked potentials. Randomized placebo-controlled double-blind (5-way) crossover study. Arzneimittelforschung 1991; 41: 427435.
  • 70
    Tarnawa I, Bolcskei H, Kocsis P. Blockers of voltage-gated sodium channels for the treatment of central nervous system diseases. Recent Pat CNS Drug Discov 2007; 2: 5778.
  • 71
    Klamt JG, Posner J. Effects of lamotrigine on pain-induced chemo-somatosensory evoked potentials. Anaesthesia 1999; 54: 774777.
  • 72
    Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45 (Suppl. 6): 1318.
  • 73
    Graversen C, Olesen SS, Olesen AE, Steimle K, Farina D, Wilder-Smith OH, Bouwense SA, van Goor H, Drewes AM. The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmaco-EEG spectral indices. Br J Clin Pharmacol 2012; 73: 363372.
  • 74
    Olesen SS, Graversen C, Olesen AE, Frokjaer JB, Wilder-Smith O, van Goor H, Valeriani M, Drewes AM. Randomised clinical trial: pregabalin attenuates experimental visceral pain through sub-cortical mechanisms in patients with painful chronic pancreatitis. Aliment Pharmacol Ther 2011; 34: 878887.
  • 75
    Persson J. Wherefore ketamine? Curr Opin Anaesthesiol 2010; 23: 455460.
  • 76
    Kochs E, Scharein E, Mollenberg O, Bromm B, Schulte am Esch J. Analgesic efficacy of low-dose ketamine. Somatosensory-evoked responses in relation to subjective pain ratings. Anesthesiology 1996; 85: 304314.
  • 77
    Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255258.
  • 78
    Fink M, Irwin P. Central nervous system effects of aspirin. Clin Pharmacol Ther 1982; 32: 362365.
  • 79
    Rohdewald P, Derendorf H, Drehsen G, Elger CE, Knoll O. Changes in cortical evoked potentials as correlates of the efficacy of weak analgesics. Pain 1982; 12: 329341.
  • 80
    Schaffler K, Reeh PW, Zentzis K, Hamperl W. Analgesic effect of acetylsalicylic acid (ASA) versus a lithium-ASA combination: an evoked potential study employing radiant heat stimulation with a CO2 laser. Pharmacopsychiatry 1987; 20: 217221.
  • 81
    Bromm B, Rundshagen I, Scharein E. Central analgesic effects of acetylsalicylic acid in healthy men. Arzneimittelforschung 1991; 41: 11231129.
  • 82
    Kobal G, Hummel C, Nuernberg B, Brune K. Effects of pentazocine and acetylsalicylic acid on pain-rating, pain-related evoked potentials and vigilance in relationship to pharmacokinetic parameters. Agents Actions 1990; 29: 342359.
  • 83
    Jones CJ. The pharmacology and pharmacokinetics of azapropazone – a review. Curr Med Res Opin 1976; 4: 316.
  • 84
    Lotsch J, Mohammadian P, Hummel T, Florin S, Brune K, Geisslinger G, Kobal G. Effects of azapropazone on pain-related brain activity in human subjects. Br J Clin Pharmacol 1995; 40: 545552.
  • 85
    Brogden RN, Heel RC, Pakes GE, Speight TM, Avery GS. Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. Drugs 1980; 20: 2448.
  • 86
    Bromm K, Herrmann WM, Schulz H. Do the B-vitamins exhibit antinociceptive efficacy in men? Results of a placebo-controlled repeated-measures double-blind study. Neuropsychobiology 1995; 31: 156165.
  • 87
    Lotsch J, Kettenmann B, Renner B, Drover D, Brune K, Geisslinger G, Kobal G. Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: relation to pharmacodynamics in an experimental pain model. Pharm Res 2000; 17: 7784.
  • 88
    Schaffler K, Reitmeir P, Gschanes A, Eggenreich U. Comparison of the analgesic effects of a fixed-dose combination of orphenadrine and diclofenac (Neodolpasse) with its single active ingredients diclofenac and orphenadrine: a placebo-controlled study using laser-induced somatosensory-evoked potentials from capsaicin-induced hyperalgesic human skin. Drugs R D 2005; 6: 189199.
  • 89
    Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 2009; 17: 275342.
  • 90
    Kobal G, Hummel C, Gruber M, Geisslinger G, Hummel T. Dose-related effects of ibuprofen on pain-related potentials. Br J Clin Pharmacol 1994; 37: 445452.
  • 91
    Lotsch J, Hummel T, Kraetsch H, Kobal G. The negative mucosal potential: separating central and peripheral effects of NSAIDs in man. Eur J Clin Pharmacol 1997; 52: 359364.
  • 92
    Hummel T, Cramer O, Mohammadian P, Geisslinger G, Pauli E, Kobal G. Comparison of the antinociception produced by two oral formulations of ibuprofen: ibuprofen effervescent vs ibuprofen tablets. Eur J Clin Pharmacol 1997; 52: 107114.
  • 93
    Seibel K, Schaffler K, Reeh P, Reitmeir P. Comparison of two different preparations of ibuprofen with regard to the time course of their analgesic effect. A randomised, placebo-controlled, double-blind cross-over study using laser somatosensory evoked potentials obtained from UV-irritated skin in healthy volunteers. Arzneimittelforschung 2004; 54: 444451.
  • 94
    Sarzi-Puttini P, Atzeni F, Lanata L, Bagnasco M, Colombo M, Fischer F, D'Imporzano M. Pain and ketoprofen: what is its role in clinical practice? Reumatismo 2010; 62: 172188.
  • 95
    Hinz B, Brune K. Paracetamol and cyclooxygenase inhibition: is there a cause for concern? Ann Rheum Dis 2012; 71: 2025.
  • 96
    Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S. Paracetamol: new vistas of an old drug. CNS Drug Rev 2006; 12: 250275.
  • 97
    Bromm B, Forth W, Richter E, Scharein E. Effects of acetaminophen and antipyrine on non-inflammatory pain and EEG activity. Pain 1992; 50: 213221.
  • 98
    Renner B, Clarke G, Grattan T, Beisel A, Mueller C, Werner U, Kobal G, Brune K. Caffeine accelerates absorption and enhances the analgesic effect of acetaminophen. J Clin Pharmacol 2007; 47: 715726.
  • 99
    Brune K. Next generation of everyday analgesics. Am J Ther 2002; 9: 215223.
  • 100
    Brogden RN. Pyrazolone derivatives. Drugs 1986; 32 (Suppl. 4): 6070.
  • 101
    Kraetsch HG, Hummel T, Lotsch J, Kussat R, Kobal G. Analgesic effects of propyphenazone in comparison to its combination with caffeine. Eur J Clin Pharmacol 1996; 49: 377382.
  • 102
    Schlicker E, Werner U, Hamon M, Gozlan H, Nickel B, Szelenyi I, Gothert M. Anpirtoline, a novel, highly potent 5-HT1B receptor agonist with antinociceptive/antidepressant-like actions in rodents. Br J Pharmacol 1992; 105: 732738.
  • 103
    Devulder J. Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs 2010; 24: 867881.
  • 104
    Kobal G, Hummel T. Effects of flupirtine on the pain-related evoked potential and the spontaneous EEG. Agents Actions 1988; 23: 117119.
  • 105
    Hummel T, Friedmann T, Pauli E, Niebch G, Borbe HO, Kobal G. Dose-related analgesic effects of flupirtine. Br J Clin Pharmacol 1991; 32: 6976.
  • 106
    Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389400.
  • 107
    Sindrup SH, Nielsen JC, Bjerring P, Arendt-Nielsen L. Imipramine does not affect argon-laser-induced pin-prick pain thresholds and laser-evoked cerebral potentials. Eur J Pain 1998; 2: 127132.
  • 108
    Curley MA, Molengraft JA. Providing comfort to critically ill pediatric patients: isoflurane. Crit Care Nurs Clin North Am 1995; 7: 267274.
  • 109
    Roth D, Petersen-Felix S, Bak P, Arendt-Nielsen L, Fischer M, Bjerring P, Zbinden AM. Analgesic effect in humans of subanaesthetic isoflurane concentrations evaluated by evoked potentials. Br J Anaesth 1996; 76: 3842.
  • 110
    Hunskaar S, Donnell D. Clinical and pharmacological review of the efficacy of orphenadrine and its combination with paracetamol in painful conditions. J Int Med Res 1991; 19: 7187.
  • 111
    Schaffler K, Reitmeir P. Analgesic effects of low-dose intravenous orphenadrine in the state of capsaicin hyperalgesia. A randomised, placebo-controlled, double-blind cross-over study using laser somatosensory evoked potentials obtained from capsaicin-irritated skin in healthy volunteers. Arzneimittelforschung 2004; 54: 673679.
  • 112
    Skrumsager BK, Ingwersen SH, Gerrits M. Safety and pharmacokinetics of ReN1869: a first human dose study in healthy subjects after single-dose administration. J Clin Pharmacol 2003; 43: 6673.
  • 113
    Schaffler K, Seibel K, Thomsen M, Edwards M. Effect of the new H1-antagonist ReN1869 on capsaicin-induced hyperalgesia in human skin. Human phase-I trial using somatosensory evoked potentials induced by a CO2 laser. Arzneimittelforschung 2004; 54: 187191.
  • 114
    Leuchter AF, Cook IA, Lufkin RB, Dunkin J, Newton TF, Cummings JL, Mackey JK, Walter DO. Cordance: a new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography. Neuroimage 1994; 1: 208219.
  • 115
    Rabinoff M, Kitchen CM, Cook IA, Leuchter AF. Evaluation of quantitative EEG by classification and regression trees to characterize responders to antidepressant and placebo treatment. Open Med Inform J 2011; 5: 18.
  • 116
    Leuchter AF, Cook IA, Gilmer WS, Marangell LB, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Fava M, Iosifescu D, Greenwald S. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res 2009; 169: 132138.
  • 117
    Bewernitz M, Derendorf H. Electroencephalogram-based pharmacodynamic measures: a review. Int J Clin Pharmacol Ther 2012; 50: 162184.
  • 118
    Treede RD, Lorenz J, Baumgartner U. Clinical usefulness of laser-evoked potentials. Neurophysiol Clin 2003; 33: 303314.
  • 119
    Bromm B, Meier W. The intracutaneous stimulus: a new pain model for algesimetric studies. Methods Find Exp Clin Pharmacol 1984; 6: 405410.
  • 120
    Lelic D, Morch CD, Hennings K, Andersen OK, Drewes AM. Differences in perception and brain activation following stimulation by large versus small area cutaneous surface electrodes. Eur J Pain 2012; 16: 827837.
  • 121
    Martin RW, Chapman CR. Dental dolorimetry for human pain research: methods and apparatus. Pain 1979; 6: 349364.
  • 122
    Cruccu G, Sommer C, Anand P, Attal N, Baron R, Garcia-Larrea L, Haanpaa M, Jensen TS, Serra J, Treede RD. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol 2010; 17: 10101018.
  • 123
    Kobal G. Pain-related electrical potentials of the human nasal mucosa elicited by chemical stimulation. Pain 1985; 22: 151163.
  • 124
    Drewes AM, Gregersen H, Arendt-Nielsen L. Experimental pain in gastroenterology: a reappraisal of human studies. Scand J Gastroenterol 2003; 38: 11151130.
  • 125
    Rossel P, Drewes AM, Petersen P, Nielsen J, Arendt-Nielsen L. Pain produced by electric stimulation of the rectum in patients with irritable bowel syndrome: further evidence of visceral hyperalgesia. Scand J Gastroenterol 1999; 34: 10011006.
  • 126
    Drewes AM, Sami SA, Dimcevski G, Nielsen KD, Funch-Jensen P, Valeriani M, Arendt-Nielsen L. Cerebral processing of painful oesophageal stimulation: a study based on independent component analysis of the EEG. Gut 2006; 55: 619629.
  • 127
    Luck SJ. Ten Simple Rules for Designing ERP Experiments. In: Event Related Potentials. A Methods Handbook, ed. Handy TC . Cambridge: MIT Press, 2004; 1732.
  • 128
    Chen ACN, Arendt-Nielsen L, Plaghki L. Laser-evoked potentials in human pain: I. Use and possible misuse. Pain Forum 1998; 7: 174184.
  • 129
    Cho CH, Jung SW, Park JY, Song KS, Yu KI. Is shoulder pain for three months or longer correlated with depression, anxiety, and sleep disturbance? J Shoulder Elbow Surg 2013; 22: 222228.
  • 130
    Negus SS, Bilsky EJ, Do Carmo GP, Stevenson GW. Rationale and methods for assessment of pain-depressed behavior in preclinical assays of pain and analgesia. Methods Mol Biol 2010; 617: 7991.
  • 131
    Khodayari-Rostamabad A, Hasey GM, Maccrimmon DJ, Reilly JP, de Bruin H. A pilot study to determine whether machine learning methodologies using pre-treatment electroencephalography can predict the symptomatic response to clozapine therapy. Clin Neurophysiol 2010; 121: 19982006.
  • 132
    Hunter AM, Leuchter AF, Cook IA, Abrams M, Siegman BE, Furst DE, Chappell AS. Brain functional changes and duloxetine treatment response in fibromyalgia: a pilot study. Pain Med 2009; 10: 730738.
  • 133
    Dimpfel W, Spuler M, Nickel B. Radioelectroencephalography (Tele-Stereo-EEG) in the rat as a pharmacological model to differentiate the central action of flupirtine from that of opiates, diazepam and phenobarbital. Neuropsychobiology 1986; 16: 163168.
  • 134
    Lorenz J, Beck H, Bromm B. Cognitive performance, mood and experimental pain before and during morphine-induced analgesia in patients with chronic non-malignant pain. Pain 1997; 73: 369375.
  • 135
    Lorenz J, Beck H, Bromm B. Differential changes of laser evoked potentials, late auditory evoked potentials and P300 under morphine in chronic pain patients. Electroencephalogr Clin Neurophysiol 1997; 104: 514521.
  • 136
    Legrain V, Mancini F, Sambo CF, Torta DM, Ronga I, Valentini E. Cognitive aspects of nociception and pain: bridging neurophysiology with cognitive psychology. Neurophysiol Clin 2012; 42: 325336.
  • 137
    Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev 2001; 53: 597652.
  • 138
    Chizh BA, Greenspan JD, Casey KL, Nemenov MI, Treede RD. Identifying biological markers of activity in human nociceptive pathways to facilitate analgesic drug development. Pain 2008; 140: 249253.
  • 139
    Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? . Nat Rev Drug Discov 2004; 3: 711715.
  • 140
    Berge OG. Predictive validity of behavioural animal models for chronic pain. Br J Pharmacol 2011; 164: 11951206.
  • 141
    Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SD. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 2012; 17: 419424.
  • 142
    Leiser SC, Dunlop J, Bowlby MR, Devilbiss DM. Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research. Biochem Pharmacol 2011; 81: 14081421.
  • 143
    Lowe PJ, Hijazi Y, Luttringer O, Yin H, Sarangapani R, Howard D. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica 2007; 37: 13311354.
  • 144
    Shankland WE 2nd. Factors that affect pain behavior. Cranio 2011; 29: 144154.
  • 145
    Coburn KL, Lauterbach EC, Boutros NN, Black KJ, Arciniegas DB, Coffey CE. The value of quantitative electroencephalography in clinical psychiatry: a report by the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 2006; 18: 460500.
  • 146
    Steiger A, Kimura M. Wake and sleep EEG provide biomarkers in depression. J Psychiatr Res 2010; 44: 242252.
  • 147
    Liberati D, DiCorrado S, Mandelli S. Topographic mapping of single sweep evoked potentials in the brain. IEEE Trans Biomed Eng 1992; 39: 943951.
  • 148
    Yordanova J, Kolev V. Single-sweep analysis of the theta frequency band during an auditory oddball task. Psychophysiology 1998; 35: 116126.
  • 149
    Gram M, Graversen C, Mørch CD, Andresen T, Drewes AM. Wavelet analysis of single-sweep pharmaco-EEG. International Pharmaco-EEG Conference New York 2012, IPEG 17th Biennial Conference 2012 Abstract Book: 65.
  • 150
    Graversen C, Olesen AE, Farina D, Drewes AM. The analgesic effect of morphine is reflected by changes in single-sweep evoked brain potentials. International Pharmaco-EEG Conference New York 2012, IPEG 17th Biennial Conference 2012 Abstract Book: 66.